Literature DB >> 29277790

Protein Expression and Genetic Variation of IL32 and Association with Colorectal Cancer in Swedish Patients.

Levar Shamoun1, Blanka Kolodziej2, Roland E Andersson3,4, Jan Dimberg5.   

Abstract

BACKGROUND: Interleukin 32 (IL32) is an intracellular pluripotent cytokine produced by epithelial cells, monocytes, T-lymphocytes and natural killer cells and seems to be involved in the pathogenesis of cancer and inflammatory diseases. Our purpose was to assess the role of protein expression and genetic polymorphisms of IL32 in colorectal cancer (CRC) susceptibility.
MATERIALS AND METHODS: To gain insight into clinical significance of IL32 in Swedish patients with CRC, using enzyme-linked immunosorbent assay, we determined whether IL32 protein level is altered in CRC tissue (n=75) compared with paired normal tissue and in plasma from patients with CRC (n=94) compared with controls (n=81). The expression of IL32 protein was confirmed by immunohistochemistry (n=73). We used Luminex technology to investigate protein levels of the cytokines IL6, tumor necrosis factor-α (TNFα) and vascular endothelial growth factor (VEGF) to relate these to IL32 levels in CRC tissue. Three single nucleotide polymorphisms (SNPs) (rs28372698, rs12934561, rs4786370) of the IL32 gene have been proposed as modifiers for different diseases. The present study evaluated the susceptibility of patients possessing these SNPs to CRC. Using TaqMan SNP genotyping assays, these SNPs were screened in Swedish patients with CRC (n=465) and healthy controls (n=331).
RESULTS: We found no significant differences in the genotypic frequencies between the patients and healthy controls and no relation to survival for any of the SNPs. However, the SNP rs12934561 was statisticalLY significant associated with older patients. IL32 protein was up-regulated in CRC tissue and related to IL6, TNFα, and VEGF, and seems to be modulated by SNP rs28372698. The IL32 protein level in CRC tissue also reflects both disseminated disease and location.
CONCLUSION: Our results suggest that altered IL32 protein concentrations in CRC tissue and genotypic variants of IL32 are related to disseminated CRC. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  IL32; SNP; colorectal cancer; protein expression

Mesh:

Substances:

Year:  2018        PMID: 29277790     DOI: 10.21873/anticanres.12225

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Genetic polymorphism patterns suggest a genetic driven inflammatory response as pathogenesis in appendicitis.

Authors:  Jan Dimberg; Marie Rubér; Marita Skarstedt; Manne Andersson; Roland E Andersson
Journal:  Int J Colorectal Dis       Date:  2019-12-16       Impact factor: 2.571

2.  Association of gene and protein expression and genetic polymorphism of CC chemokine ligand 4 in colorectal cancer.

Authors:  Levar Shamoun; Kalle Landerholm; Amanda Balboa Ramilo; Roland E Andersson; Jan Dimberg; Dick Wågsäter
Journal:  World J Gastroenterol       Date:  2021-08-14       Impact factor: 5.742

3.  Effects of IL-32 polymorphisms and IL-32 levels on the susceptibility and severity of coronary artery disease.

Authors:  Susu Jin; Xiujing Liu; Yingying Wang; Jian Yu; Minghua Jiang
Journal:  J Clin Lab Anal       Date:  2021-11-19       Impact factor: 2.352

Review 4.  A Paradoxical Effect of Interleukin-32 Isoforms on Cancer.

Authors:  Saerok Shim; Siyoung Lee; Yasmin Hisham; Sinae Kim; Tam T Nguyen; Afeisha S Taitt; Jihyeong Hwang; Hyunjhung Jhun; Ho-Young Park; Youngmin Lee; Su Cheong Yeom; Sang-Yeob Kim; Yong-Gil Kim; Soohyun Kim
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

5.  Associations between Interleukin-32 Gene Polymorphisms rs12934561 and rs28372698 and Susceptibilities to Bladder Cancer and the Prognosis in Chinese Han Population.

Authors:  Jie Yang; Zhongyu Jian; Pengfei Shen; Yunjin Bai; Yin Tang; Jia Wang
Journal:  Dis Markers       Date:  2020-11-05       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.